Biomarkers /
CCND3
Overview
Cyclin D3 (CCND3) is a gene that encodes a protein that functions in the regulation of CDK kinases in the cell cycle. Fusions, missense mutations, nonsense mutations, silent mutations, and frameshift deletions and insertions are observed in cancers such as endometrial cancer, skin cancer, and stomach cancer.
CCND3 is altered in 1.11% of all cancers with lung adenocarcinoma, breast invasive ductal carcinoma, colon adenocarcinoma, diffuse large B-cell lymphoma, not otherwise specified, and esophageal adenocarcinoma having the greatest prevalence of alterations [3].
The most common alterations in CCND3 are CCND3 Amplification (0.59%), CCND3 Mutation (0.47%), CCND3 Q276* (0.04%), CCND3 Loss (0.03%), and CCND3 P284S (0.03%) [3].
Clinical Trials
Significance of CCND3 in Diseases
References
1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.